Tioguanine, hydroxyurea

neutrophil index

HBcAb+, HBsAb-打rituximab ETV預防要吃到治療結束後一年

HBcAb+建議驗HBV DNA

AML

APL: keep Plt > 50k; 開始吃ARTA後平均35天血球才會穩定

ATRA: diplopia，眼底像IICP

ATRA+arsenic trioxide: not yet proven in high-risk group due to low number of patients

• Leukostasis → hydroxyurea
• FIxed-dose ATO
• Oral ATO

ATRA易產生thrombosis → 勿用transamin

Maintain: 6-MP + MTX易造成嚴重cytopenia不好調藥

Myeloid sarcoma: t(8;21), inv(16)

t(8;21): dimCD19

TP53 mutation → complex karyotype

APL: no CD34 (最早loss), HLA-DR, CD15; high cMPO (if low → DIC)

Monocyte: persistent HLA-DR

M4&5: ↑ skin, gingiva, CNS involvement; CD56 (+) → extramedullary risk